New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
07:48 EDTADXSAdvaxis, University of Pennsylvania restructure license agreement
Advaxis and the University of Pennsylvania signed an amendment to restructure their 2002 Exclusive License, which relates to Advaxis' proprietary Listeria monocytogenes Lm-LLO cancer immunotherapy technology. The restructured agreement eliminates a milestone payment due upon the commencement of a Phase 3 clinical trial in humans and modifies milestone payments relating to first regulatory approval which Advaxis would owe to Penn. In exchange, Penn will receive an increased royalty rate on net sales, as well as enhanced milestone payments from Advaxis when cumulative global sales of between $250M and $2B are reached. The amended agreement allows Advaxis to more fully utilize its financial resources on the current clinical development of its Lm-LLO cancer immunotherapy technology and it provides Penn with enhanced post-commercialization financial terms.
News For ADXS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
16:26 EDTADXSAdage Capital Partners reports 18.84% passive stake in Advaxis
Subscribe for More Information
December 15, 2014
07:33 EDTADXSAdvaxis announces FDA acceptance of INDA to commence clinical trials of ADXS-HPV
Subscribe for More Information
December 8, 2014
09:20 EDTADXSOn The Fly: Pre-market Movers
Subscribe for More Information
07:35 EDTADXSAdvaxis reports FDA acceptance of IND application for ADXS-PSA combination trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use